All Blogs
Feb 24, 2025
The Parkinson’s Treatment Landscape: Progressing Too Slowly for an Expanding Patient Base
Parkinson’s disease, a progressive neurodegenerative disorder, is emerging as a significant health challenge in the United States and globally, primarily due to an aging population. This condition, characterized by motor symptoms such as tremors, muscle rigidity, and slowed movement, along with numerous non-motor s...
Read More...
Feb 21, 2025
J&J’s SPRAVATO Achieves Milestone with Monotherapy Approval in Depression Treatment
Johnson & Johnson’s SPRAVATO, which is already on track to become a blockbuster drug, has received a significant boost with the FDA’s approval for its use as a standalone treatment for major depressive disorder (MDD). Initially approved in 2019, SPRAVATO was authorized for use alongside an oral antidepressant i...
Read More...
Feb 20, 2025
FDA Grants 510(k) Clearance to Neonav® ECG Tip Location System; ClearPoint Neuro Secures EU MDR Certification for SmartFlow Cannula; Volta Medical’s AI-Driven Ablation Procedure Improves Outcomes in Persistent Atrial Fibrillation Trial; WhiteSwell Presents New Clinical Data on eLym System for Acute Heart Failure Treatment; J&J MedTech Introduces CEREGLIDE™ 92 Catheter System; Thermo Fisher Launches New Spatial Imaging System for Tissue Proteomics
Neonav® ECG Tip Location System Received FDA 510(k) Clearance to Improve Pediatric Vascular Access Care On February 16, 2025, Navi Medical Technologies, a leader in pediatric healthcare innovation, announced that its Neonav® ECG Tip Location System received 510(k) clearance from the U.S. Food and Drug Admi...
Read More...
Feb 19, 2025
The Rise of Peptide Drug Conjugates: A Promising Approach for Drug Delivery
Peptide drug conjugates (PDCs) represent a groundbreaking approach in targeted therapy, offering a powerful strategy for treating diseases, particularly cancer. Peptide drug conjugates are a class of biopharmaceuticals that combine a therapeutic peptide with a cytotoxic or biologically active drug. The peptide serv...
Read More...
Feb 18, 2025
EU Approves Galderma’s NEMLUVIO for Atopic Dermatitis and Prurigo Nodularis; GSK’s Penmenvy Wins FDA Nod; Ono Pharmaceuticals’ ROMVIMZA Gets Green Light from FDA for Symptomatic TGCT; Bristol Myers Squibb Updates on RELATIVITY-098 Phase III Trial Findings; FDA Expands Label for Astellas’ IZERVAY in Geographic Atrophy Treatment
EU Approves Galderma’s NEMLUVIO for Atopic Dermatitis and Prurigo Nodularis Galderma has announced that the European Commission has approved NEMLUVIO in the European Union (EU) to treat both moderate-to-severe atopic dermatitis and prurigo nodularis. The approval allows Nemluvio to be used subcutaneously for pat...
Read More...
Feb 17, 2025
Vertex’s JOURNAVX: A Historic Milestone in Pain Treatment After a Long Dry Spell
A week after Purdue Pharma and the Sackler family agreed to a $7.4 billion settlement over lawsuits related to the opioid painkiller OxyContin, the FDA approved Vertex’s suzetrigine, marking the first novel mechanism for acute pain relief in over 20 years—potentially reshaping the treatment landscape. ...
Read More...
Feb 14, 2025
Beyond Supportive Care: How New Drugs are Shaping Metabolic-associated Steatohepatitis (MASH) Treatment Outcomes
Metabolic-associated Steatohepatitis (MASH), previously known as Non-alcoholic Steatohepatitis (NASH), is a progressive liver condition characterized by fat buildup, inflammation, and liver cell damage. With rising rates of obesity, diabetes, and metabolic syndrome worldwide, MASH is becoming a major public health ...
Read More...
Feb 13, 2025
Agiliti Launches Essentia; KUBTEC Introduces PICASSO Plus; FDA Clears Neuvotion’s NeuStim™ for Non-Invasive Hand Stimulation in Stroke & SCI Patients; Ibex Medical Analytics Achieves Milestone with FDA 510(k) Clearance; BlueWind Medical Reports Strong Two-Year Outcomes for Revi® System in Peer-Reviewed Study; Reprieve Cardiovascular’s FASTR Pilot Trial Shows Positive Outcomes, FDA Approves IDE for Next Phase
Agiliti Launched Essentia, an Innovative Multi-Acuity Hospital Bed that Helps Lower Patient Risk and Accelerate Mobility On February 11, 2025, Agiliti, a prominent manufacturer and provider of medical device solutions for the U.S. healthcare industry, introduced Essentia™, a versatile multi-acuity bed fram...
Read More...
Feb 12, 2025
Medication Management Systems: The Key to Optimizing Pharmaceutical Care
Medication management is a critical aspect of healthcare that ensures patients receive the right medication, in the correct dosage, at the appropriate time, and for the intended purpose. With increasing complexity in treatment regimens and rising incidences of medication errors, an effective medication management s...
Read More...
Feb 11, 2025
Immix Bio’s NXC-201 Gets FDA RMAT for AL Amyloidosis; Biodexa’s eRapa Wins Fast Track for Familial Adenomatous Polyposis; AbbVie’s EMBLAVEO Approved for Complicated Intra-Abdominal Infections; Insmed’s Brensocatib Gains Priority Review for Bronchiectasis; Aro Bio’s ABX1100 IND Cleared for Pompe Disease
Immix Biopharma's NXC-201 Receives FDA RMAT Designation for Relapsed/Refractory AL Amyloidosis Immix Biopharma has received the FDA’s RMAT (Regenerative Medicine Advanced Therapy) designation for NXC-201, a sterically optimized CAR-T therapy for relapsed/refractory AL amyloidosis. The designation is granted to r...
Read More...